WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017202003) GLYCOGEN PHOSPHORYLASE INHIBITOR AND PREPARATION METHOD AND USE THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/202003 International Application No.: PCT/CN2016/108865
Publication Date: 30.11.2017 International Filing Date: 07.12.2016
IPC:
C07J 43/00 (2006.01) ,A61K 31/58 (2006.01) ,A61P 3/10 (2006.01) ,A61P 3/06 (2006.01) ,A61P 9/12 (2006.01) ,A61P 9/10 (2006.01) ,A61P 3/04 (2006.01) ,A61P 3/00 (2006.01)
Applicants: SOUTH CHINA UNIVERSITY OF TECHNOLOGY[CN/CN]; No. 381 Wushan Road, Tianhe District Guangzhou, Guangdong 510640, CN
Inventors: LI, Jing; CN
ZHANG, Liying; CN
ZHANG, Lei; CN
Agent: GUANGZHOU HUAXUE INTELLECTUAL PROPERTY AGENCY CO., LTD.; 1st Floor, Material Building No. 381 Wushan Road, Tianhe District Guangzhou, Guangdong 510640, CN
Priority Data:
201610362207.225.05.2016CN
Title (EN) GLYCOGEN PHOSPHORYLASE INHIBITOR AND PREPARATION METHOD AND USE THEREOF
(FR) INHIBITEUR DE LA GLYCOGÈNE PHOSPHORYLASE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
(ZH) 一种糖原磷酸化酶抑制剂及其制备方法和应用
Abstract: front page image
(EN) Disclosed is a compound of formula (I) as a glycogen phosphorylase inhibitor or a pharmaceutically acceptable salt or ester thereof, wherein formula (I) is as defined in the description. The effect of the compound on inhibiting glycogenolysis on a cellular level is equivalent to that of PSN-357. The compound can be used in preparing drugs for preventing and treating diabetes and complications thereof, hyperlipidemia, hypertension and complications thereof, atherosclerosis, obesity and metabolic syndromes.
(FR) L'invention concerne un composé de formule (I) servant d'inhibiteur de la glycogène phosphorylase ou un sel ou ester pharmaceutiquement acceptable de celui-ci, la formule (I) étant telle que définie dans la description. L'effet du composé sur l'inhibition de la glycogénolyse au niveau cellulaire est équivalent à celui du PSN-357. Le composé peut être utilisé dans la préparation de médicaments destinés à prévenir et traiter le diabète et ses complications, l'hyperlipidémie, l'hypertension et ses complications, l'athérosclérose, l'obésité et le syndrome métabolique.
(ZH) 一种作为糖原磷酸化酶抑制剂的式(I)化合物或其药学上可接受的盐或酯,其中式(I)如说明书所定义。所述化合物在细胞水平的抑制糖原分解作用与PSN-357相当,可用于制备预防和治疗糖尿病及其并发症、高血脂症、高血压及其并发症、动脉粥样硬化症、肥胖、代谢综合症的药物。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)